These findings suggest that in DLBCL cells, MYCT1 inhibits the binding ability of the latter to the RUNX1 promoter region by binding to MAX, thereby inhibiting the expression of RUNX1. The gene discussed is MYCT1; the disease is diffuse large B-cell lymphoma.